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Abstract
Background: The SDHA, SDHB, SDHC and SDHD genes encode the subunits of succinate
dehydrogenase (succinate: ubiquinone oxidoreductase), a component of both the Krebs cycle and
the mitochondrial respiratory chain. SDHA, a flavoprotein and SDHB, an iron-sulfur protein
together constitute the catalytic domain, while SDHC and SDHD encode membrane anchors that
allow the complex to participate in the respiratory chain as complex II. Germline mutations of
SDHD and SDHB are a major cause of the hereditary forms of the tumors paraganglioma and
pheochromocytoma. The largest subunit, SDHA, is mutated in patients with Leigh syndrome and
late-onset optic atrophy, but has not as yet been identified as a factor in hereditary cancer.
Description:  The SDH mutation database is based on the recently described Leiden Open
(source) Variation Database (LOVD) system. The variants currently described in the database were
extracted from the published literature and in some cases annotated to conform to current
mutation nomenclature. Researchers can also directly submit new sequence variants online. Since
the identification of SDHD, SDHC, and SDHB as classic tumor suppressor genes in 2000 and 2001,
studies from research groups around the world have identified a total of 120 variants. Here we
introduce all reported paraganglioma and pheochromocytoma related sequence variations in these
genes, in addition to all reported mutations of SDHA. The database is now accessible online.
Conclusion: The SDH mutation database offers a valuable tool and resource for clinicians involved
in the treatment of patients with paraganglioma-pheochromocytoma, clinical geneticists needing an
overview of current knowledge, and geneticists and other researchers needing a solid foundation
for further exploration of both these tumor syndromes and SDHA-related phenotypes.
Background
Pheochromocytoma is a tumor of the sympathetic nerv-
ous system, arising in the chromaffin cells of the adrenal
medulla. Tumors also occur in related sympathetic gan-
glia and are properly described as paragangliomas, by ana-
tomical location. Both these tumor types are generally
catecholamine secreting. Paragangliomas of the head and
neck (HN PGL) are related tumors which are rarely cate-
cholamine secreting, arise in the parasympathetic ganglia,
most commonly in the carotid body, but also frequently
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found as vagal and jugulotympanic tumors. The heredi-
tary element in these tumors has long been recognized [1]
and a putative genetic locus for PGL1 was first mapped in
1992 by Heutink et al. [2,3]. The identification of PGL1
followed, when Baysal et al. [4] reported germline muta-
tions in the gene encoding succinate dehydrogenase, sub-
unit D (SDHD) in PGL1-linked families. A candidate gene
approach quickly identified germline mutations in the
other SDH subunits, SDHC (PGL3) [5] and SDHB (PGL4)
[6]. It is now recognised that SDHD and SDHB, together
with the VHL, RET and NF1 genes, play a major role in the
hereditary forms of both pheochromocytoma and para-
ganglioma [7]. In contrast, mutations of SDHA result in a
range of clinical phenotypes, including Leigh syndrome,
but have never been reported in relation to HN PGL or
pheochromocytoma.
The SDH genes encode subunits of the heterotetrameric
succinate dehydrogenase complex, a component of both
the mitochondrial-respiratory chain (complex II) and the
Krebs cycle. SDHA (Ch5p15) and SDHB (Ch1p36)
encode the two catalytic subunits, the flavoprotein and
the iron-sulfur protein respectively; SDHC (Ch1q21) and
SDHD (Ch11q23) encode transmembrane proteins that
anchor complex II in the inner mitochondrial membrane,
and contain a ubiquinone binding site. The SDHA gene
consists of 15 exons, with a second isoform [8] and at least
one pseudogene (Ch3q29) present in the genome. SDHB
has eight exons and no known pseudogenes, while SDHC
covers six exons and has three candidate pseudogenes.
SDHD has four exons and six reported intronless pseudo-
genes [9].
Construction and content
The SDH mutation database [10] is based on the recently
described Leiden Open (source) Variation Database
(LOVD) system [11]. Researchers may submit new
sequence variants online and submitters can access and
edit their personal data at any time. During the submis-
sion procedure researchers will be asked to fill in several
fields on the submission form, providing those data that
are deemed absolutely essential for mutation databases by
the Human Genome Organization Mutation Database
Initiative. These include a patient ID, an exact molecular
description of the variant (DNA-level), and details about
the source of the material and detection method used.
Mutations are described in accordance with the recom-
mendations of the Human Genome Variation Society
(HGVS), update August 2004, and it should be noted that
the current nomenclature can differ significantly from pre-
vious versions [12] and from that used in the literature.
Newly submitted data are forwarded automatically to the
database curators and each variant is given a unique iden-
tifier as recommended by Claustres et al. [13]. After the
curator's approval the new variant is automatically
included in the database and all connected web pages are
updated instantly.
The SDH database [10] includes (as of September 2005)
120 variants of which 98 are thought to be pathogenic
and 22 non-functional variants (polymorphisms). The
most common types of mutations are missense and non-
sense, with relatively frequent small deletions and small
insertions. Missense mutations are the most common
form but still occur at half the expected relative frequency
A partial overview of the SDHD table of allelic variants Figure 2
A partial overview of the SDHD table of allelic variants.
The introductory page of the SDHD mutation database Figure 1
The introductory page of the SDHD mutation database. In 
addition to summary tables, various search options are also 
available.BMC Medical Genetics 2005, 6:39 http://www.biomedcentral.com/1471-2350/6/39
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when compared to the mutation summary of the Human
Gene Mutation Database. Reports of large deletions are
sparse but this may simply reflect limited effort in this
direction to date.
Inclusion of sequence variants in the SDH mutation data-
base does not imply that there is convincing evidence for
pathogenicity. Please refer to the disclaimer on the web-
site.
Within the SDH database, all variants that disrupt the
reading frame, affect highly conserved residues or disrupt
the consensus donor or acceptor splice sites (GT-AG), and
are not found in healthy controls, can be considered to be
pathological.
In the case of non-conserved missense variants and poten-
tial splice site mutations that do not disrupt the consensus
splice sites, a designation of "unclassified variants" (UV)
should eventually be developed. The CMGS guidelines
(CMGS Best Practice Guidelines – Molecular Genetics
Service Testing for HNPCC) suggest that several lines of
supporting evidence can be valuable, including screening
a panel of normal DNA from 50–200 individuals to rule
out a common polymorphism, describing the nature of
the amino acid change (conservative or non-conservative)
and the significance of the position in the coding
sequence (evolutionarily conserved or known functional
domain). Confidence increases if the mutation has been
previously described, in several families, and if it segre-
gates with the disease within the family. However none of
these factors can be taken as definitive and each variant
must be considered on its merits. Unfortunately, most
mutations are currently reported without this accompany-
ing analysis, and many have been identified in a single
case or family. Thus caution should be exercised when
attempting to derive clinically relevant information from
the database, and all the evidence in the database and any
additional data must be carefully weighed by users.
Polymorphisms, including intron variants, synonymous
(silent) variants, nonsynonymous missense variants
found in a healthy control panel (e.g. p.His50Arg of
SDHD) and potential non-consensus splice site muta-
tions but without evidence for transcript rearrangements
are included in the database as such unless accompanied
by clear evidence of pathogenic potential.
The database includes a brief description of the tumor
types presenting in carriers, and an explanation of the
abbreviations is included. Under "remarks" the country of
origin of patients (if reported), or of the study itself, is
included to aid the identification of founder mutations,
already known to play a major role in the incidence of
hereditary HN PGL in the Netherlands. In addition other
relevant information, such as the number of healthy con-
trols tested for the variant, and further supporting evi-
dence, is described.
Other columns detail the number of reported familial
'carriers or cases' (not generally distinguishable in current
literature) and the number of 'sporadic' cases (those with
no known familial antecedents). For further details, the
'full legend' feature can be consulted.
While the description of many mutations reported in the
literature remains unchanged, many others have been
adapted to the standardized nomenclature, or in the case
of frameshifts, have been fully annotated in the long ver-
sion which includes the length of the additional amino
acid chain that results. That a standardized nomenclature
provides clarity is seen in several cases where authors have
reported "novel" mutations, when in fact the same muta-
tion had already been described but using a different
Table 1: A summary of all allelic variants in the SDH mutation database as of September 2005.
Gene
Sequence Variant SDHA SDHB SDHC SDHD Total
Total – Sequence Variants 5 60 5 50 120
Total – Mutations 5 47 4 42 98
Missense 4 19 1 11 36
Nonsense (incl. start codon) 1 8 1 11 21
Small Insertions <10 bp 0 4 0 3 7
Small Deletions <10 bp 0 9 0 13 22
Splice site 0 6 1 2 9
Large Insertions/deletions 0 1 1 2 4
Total – Polymorphisms 0 13 1 8 22
Synonymous (Silent) 0 3 0 4 7
Non-Synonymous 0 1 0 2 3
Promoter or Intron polymorphisms 0 9 1 2 12BMC Medical Genetics 2005, 6:39 http://www.biomedcentral.com/1471-2350/6/39
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sequence annotation or nomenclature. To avoid confu-
sion and aid reference to original sources, the annotation
used in the original report is included in the 'original
description' column.
Utility
The SDH mutation database is organized in a gene and
exon centered fashion, and as such will be particularly
useful to clinical geneticists, providing an up-to-date over-
view of all known SDH mutations. The database will also
be of interest and useful to general and specialist physi-
cians involved in the care and treatment of patients with
pheochromocytoma, paraganglioma and complex II defi-
ciencies including Leigh syndrome.
The four SDH genes each have a separate database with a
summary page listing general gene and database informa-
tion and providing access to the tables containing the
allelic variant information and several search options (Fig.
1). The complete allelic variant table contains the
sequence variations ordered by position relative to the
cDNA reference sequence (Fig. 2).
Since the first description of mutations of SDHD, SDHB
and SDHC in paraganglioma and pheochromocytoma, a
series of reports have appeared describing a total of 47 dis-
tinct mutations in SDHB and 42 in SDHD (Table 1).
While patterns already seem to be emerging (discussed
below), given the number of SDHB and SDHD mutations
currently known, it is important to realize that any conclu-
sions must be seen as provisional, and only an expansion
of the database will allow more definite conclusions to be
drawn.
Phenotype
Patients with mutations of SDHB and SDHD have
recently been shown to display distinct clinical pheno-
types [14]. This finding is clearly reflected in the SDH
database (Fig. 2).
Missense vs. nonsense
An interesting feature of the current SDHB-SDHD muta-
tion spectrum is the difference in the frequency of mis-
sense mutations in contrast to truncating mutations
(nonsense, frameshift, splice site and major deletions).
While missense mutations are relatively more common in
SDHB, truncating mutations are more frequent in SDHD
(Table 2). The larger number of missense mutations
observed in SDHB suggests that the SDHB protein is
under greater structural constraint than the SDHD pro-
tein, which is also reflected by a higher degree of conser-
vation for SDHB. Thus the weaker conservation of SDHD
may allow more non-deleterious missense changes and
require frameshift and truncating mutations before a
pathogenic effect is seen. The missense mutations of
SDHB cluster in several regions, including the iron-sulfur
clusters, while the missense mutations of SDHD seem to
cluster around the three transmembrane domains.
Exon distribution
A further striking difference is in the distribution of muta-
tions over the exons of the respective genes. SDHD muta-
tions are found evenly distributed over the four exons
while mutations of SDHB are concentrated in certain
exons, most notably exon 2 (16 mutations) and are
entirely absent from exons 5 and 8 (Fig. 3).
SDHA and SDHC
A striking discrepancy has arisen between the numbers of
mutations reported in the SDHB and SDHD genes and
those of SDHA and SDHC. The divergent phenotype asso-
ciated with SDHA, Leigh syndrome or Leigh-like symp-
toms, and the predominantly recessive inheritance
pattern may partly explain the paucity of reported muta-
tions in this gene. More curious, however is the small
number of SDHC mutations reported, despite inclusion
of SDHC in many of the screening efforts of paragangli-
oma/pheochromocytoma patients [15-22]. To date 42 dif-
ferent pathogenic mutations have been reported to affect
the 159 amino acid SDHD protein while only four have
been found affecting the 169 amino acids of the SDHC
protein.
Discussion
The SDH database provides the only complete and up-to-
date overview of all disease-related gene variants reported
in SDH subunits. In addition, columns describing sup-
porting evidence and clinical features provide a starting
point for further exploration of the possible relevance of
each variant. An example of utility is the clear divergence
Table 2: Differing frequencies of missense mutations vs. truncating mutations (nonsense, frameshift, splice site and major deletions) in 
SDHB and SDHD.
Gene SDHB % SDHD %
Type of Variant
M i s s e n s e 1 94 01 12 6
Truncating (incl. splice site) 28 60 31 74
Total 47 42BMC Medical Genetics 2005, 6:39 http://www.biomedcentral.com/1471-2350/6/39
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in clinical phenotypes between SDHB and SDHD (Fig. 2),
supporting the conclusions of Neumann et al [14]. In the
future, we hope to link this gene-centered database to clin-
ically-oriented databases of HN PGL and SDH-related
pheochromocytoma, allowing closer gene-phenotype and
mutation-phenotype correlations.
A striking feature of the SDH database is the eight-fold
greater number of reported mutations in SDHB and
SDHD compared to SDHA and SDHC. This is perhaps
unexpected in that all are subunits of a single protein
complex, and, in yeast, mutation in any one of the four
genes leads to loss of SDH function and an inability to
grow by respiration [23]. An explanation, in the case of
SDHA, may be the presence in the genome of a second
isoform [8] and the fact that known human SDHA muta-
tions do not lead to complete loss of the electron transfer
function [24]. The discrepancy in mutation frequency in
SDHC and SDHD is more difficult to explain due to our
present view of the structural and functional equivalence
of these proteins. At least eight studies have failed to find
mutations of SDHC in paraganglioma and pheochromo-
cytoma patients. Although the SDHC gene, on chromo-
some 1, might be more commonly affected by major
deletions, it is possible that another genetic mechanism
might explain the discrepancy. Recent evidence suggests
that additional genetic factors located on chromosome 11
may, together with SDHD, play a role in the tumorigene-
sis of HN PGL and pheochromocytoma [25,26].
Conclusion
The variation in both phenotypes and mutation frequen-
cies amongst the four subunits of complex II and our cur-
rent inability to provide an explanation illustrates how
little we still know about both the diseases in question
and the biological functions of complex II. Knowledge
brings understanding and a database of all known muta-
tions in the genes encoding SDHA, B, C, and D will, we
believe, represent a valuable tool and resource for both
clinicians involved in the treatment of paraganglioma and
pheochromocytoma patients, clinical geneticists needing
a overview of current knowledge, and geneticists and
other researchers needing a solid foundation for further
exploration of the genetic aspects of these tumor syn-
dromes, SDH function, and SDHA related phenotypes.
Availability and requirements
The SDH mutation database is freely accessible to all at
http://chromium.liacs.nl/lovd_sdh/.
All researchers may submit new sequence variants online
(after registration – to collect contact information for ref-
erence purposes and clarification of submitted details, as
well as to assign a login name and password).
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